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ABSTRACT 
Multiple sclerosis (MS) is a common chronic autoimmune and neurodegenerative disease of 
the central nervous system (CNS). MS is a debilitating disease that affects young adults, 
especially females. Why we develop MS? Is thought to be a consequence of our genes and the 
environment. In the past four years, the number of MS associated genetic variants have 
increased up to more than 200, however they explain only about 30% of its heritability.  
The general aim of the research presented in this thesis is to explore genetic variants associated 
to MS and to employ our knowledge of the known associations to study their potentiality as 
biomarkers. 
In paper I, we aimed to identify genetic variants that distinguish the relapsing relapsing 
remitting (RR)MS from the primary progressive (PP)MS courses using whole exome 
sequencing data. We report a number of common and rare variants that are associated to either 
course. Moreover, we identified enrichment of mutations of other progressive neurological 
disorders in PPMS patients. 
In paper II we investigated the possibility of somatic mosaicism within the CNS resulting in 
sub-populations of cells involved in MS pathogenesis.  We identified somatic genetic variants 
of the copy number variations (CNVs) type in the T cell receptor loci. These CNVs lead us to 
profile and compare the TCR repertoire in cells in the periphery and in the CNS. 
A number of potent treatments have been introduced for treating MS patients and they 
succeeded in providing a better quality of life. In papers III and IV, based on the available 
information of MS associated genetic variants we studied the effects of two drugs, natalizumab 
and fingolimod, on the intra-individual profile of proteins within selected pathways with the 
ambition to identify biomarkers for MS treatment. We took a candidate gene approach in paper 
III and studied the treatment effects on soluble cytokine receptors and observed changes in 
plasma levels of sIL-7Rα, sIL-2Rα and sgp130. In paper IV we took a multiplex approach 
utilizing protein arrays and detected a decrease in plasma levels of nine proteins during 
natalizumab treatment. Furthermore, we validated and replicated the change for the most 
significant protein, PEBP1.  
Hopefully the identified genetic variants and observed changes on the molecular level during 
treatment could pave the way to hypotheses generation in order to identify pathways affected 
by these variations and provide insight into the immunopathology of MS. 
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1 INTRODUCTION 
1.1 MULTIPLE SCLEROSIS 
Multiple sclerosis (MS) is a chronic autoimmune and neurodegenerative disease of the central 
nervous system (CNS)1. After trauma MS is one of the most common causes for neurological 
disability in young adults. The description of MS can be followed back as early as to the 14th 
century in documents from the Vatican describing a Dutch nun, Saint Ludwina of Schiedam, 
who experienced episodes of leg weakness and visual disturbances interrupted by remission2. 
Five centuries later, it was the French neurologist Jean-Martin Charcot who connected both the 
neurological symptoms and pathological findings with the brain and the spinal cord, and 
recognized this as a distinct neurological disease, giving it the name “sclerose en plaques”3. 
The name is based on the appearance of disseminated demyelinated nervous tissue and axonal 
loss, involving destruction of the myelin producing cells (the oligodendrocytes) and loss of the 
myelin sheath covering the neuronal axons (crucial for action potential and nerve signal 
propagation), resulting in subsequent axonal damage 1.  
1.1.1  Epidemiology of MS 
There are about 2-2,5 million MS patients worldwide and MS has an asymmetrical distribution, 
with high prevalence in northern European and American populations4. There is a strong 
association between the prevalence of MS and global latitudes, the higher the latitude the higher 
the prevalence5. Some regions do not agree with the latitude gradient distribution, such as the 
indigenous Sami population in Scandinavia that has a low prevalence of MS. The prevalence 
of MS in Sweden is 188.9/100,000 individuals, with a female to male ratio of 2.35:16.  
1.1.2 MS clinical manifestation and diagnosis 
MS patients usually experience their first symptoms when they are 20 to 40 years old. After 
experiencing the first neurological episode the patient is considered as clinically isolated 
syndrome (CIS). However, when typical MS magnetic resonance image (MRI) lesions are 
detected with the absence of clinical signs and symptoms, the patient is considered to suffer 
from radiologically isolated syndrome (RIS). CIS and RIS patients will be followed over time 
up to see if the patients develop MS.  MS has different courses; 85% of the patients have a 
relapsing-remitting (RRMS) course, during which the patient has alternating periods of 
neurological disabilities and recoveries or in other words periods of relapses and remissions. 
When the disabilities start to accumulate and there is no recovery, RRMS usually advances to 
secondary progressive MS (SPMS). In the primary progressive MS (PPMS) course, 
representing 10-15% of MS patients and usually with an older age of onset than the RRMS, 
the patient’s condition worsens from the beginning and continues developing neurological 
signs and symptoms without periods of recovery7 (Figure 1).  
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Figure 1. Different courses of MS; RRMS (A), SPMS (B), PPMS (C) 
In order to make it easier for neurologists to decide on the right diagnosis earlier and at the 
same time avoiding a faulty diagnosis, the International Panel on the Diagnosis of Multiple 
Sclerosis formulated the McDonald criteria for MS diagnosis8. In summary, a diagnosis 
according to these criteria is based on the number of relapses, taking into account the 
dissemination in space and time, and aided by paraclinical methods, which are the detection of 
oligoclonal bands (OCBs) in the cerebrospinal fluid (CSF) with absence in the serum and 
magnetic resonance imaging (MRI) of the lesions. MS diagnosis could be reached without the 
help of paraclinical methods if the patient experiences two or more relapses which are separated 
in both time and space. Continuous reviews and revisions of the McDonalds criteria have been 
done since its presentation9,10. A grading system is used to assess the level of disability in MS 
patients, the Expanded Disability Status Scale (EDSS)11. The scale extends from normal (=0) 
to death from MS (=10).  
1.1.3 MS central nervous system pathology 
During the RRMS course the axonal demyelination is considered to result in blockade of the 
nerve signals and development of neurological symptoms. After cessation of the inflammatory 
process, limited remyelination of the axons results in remission12. Clinical symptoms usually 
mirror the site of the lesion in the CNS and the appearance of these lesions are commonly 
associated with the blood brain barrier (BBB) being breached by autoreactive immune cells, 
development of inflammation at different sites and demyelinated plaques13. These 
demyelinated plaques are the pathological hallmark of MS and they also contain limited 
preserved axons and astrocytic scars. They can randomly present within areas of the CNS, but 
certain areas are more inclined to be affected; optic nerves, brainstem, cerebellar white matter, 
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periventricular and subcortical white matter and the cervical segments of the spinal cord, and 
they often surround large or medium sized veins. Demyelination in MS has for a long time 
been thought to occur only in the white matter, considering MS a white matter disease, but the 
truth is that demyelination can appear extensively in the gray matter, especially in the cortex. 
In addition, neuronal and axonal loss and atrophy can be found in the demyelinated and non-
demyelinated cortical gray matter areas even in a global manner. MS brains are also affected 
in a global manner, especially for SPMS and PPMS. Despite retaining myelin, the normal 
appearing white matter (NAWM) is chronically injured, characterized by diffuse inflammation 
consisting of small perivascular inflammatory cuffs and microglial activation forming 
microglia nodules, in addition to the presence of axonal injury independently of demyelination. 
These diffuse changes in the NAWM result in global brain atrophy 14. Taking into consideration 
the focal demyelinated lesions in the white matter and also the gray matter and the diffused 
axonal loss and inflammation in the NAWM, one can conclude that MS is a CNS global 
phenomena involving neuro-inflammation and neurodegeneration.  
1.1.4 Autoimmunity in MS 
1.1.4.1 CD4 and CD8 T cells 
Most experts in the MS immunity field agree with the hypothesis that MS pathogenesis 
involves activation of CD4 T cells in the periphery by self-myelin antigens, followed by 
activated cells crossing the BBB and initiating the inflammatory process. This hypothesis is 
supported both by the MS experimental model, experimental autoimmune encephalomyelitis 
(EAE), in which an MS like disease is induced by myelin specific CD4 T cells, and by genetic 
studies which show that HLA class II loci show the strongest association to MS risk. Even 
though there is a majority agreement on this hypothesis, there is still somewhat of a mystery as 
to where these CD4 T cells are activated and which antigens specifically activate them. These 
antigens could be self CNS antigens or cross-reactive antigens. Cross-reactivity occurs when 
foreign antigens, such as viral antigens, have similar peptide sequences to CNS antigens and 
might activate CD4 T cells in the periphery which subsequently may be exposed to CNS 
antigens resulting in reactivation of these cells. This is termed molecular mimicry. Several 
studies have shown the presence of these myelin autoreactive CD4 T cells in the circulation of 
MS patients and also in controls, but in much lower frequencies. These autoreactive cells were 
also shown to be able to secrete the inflammatory cytokine Interferon g (IFN-g). CD8 T cells 
are also implicated in causing CNS tissue damage, but they are not as well studied in the context 
of MS as CD4 T cells and are thought to be involved more in the chronic phase15. CD8 T cells 
are more abundant in the MS lesions than the CD4 T cells16,17 and show clonal expansion18. 
Genetic studies also advocate the role of CD 8 T cells, as alleles in the HLA class I region have 
been associated with MS, HLA-A*02:01 being protective and HLA-A*03:01 increasing the risk 
19,20. This makes sense because neurons and axons express the major histocompatibility 
complex (MHC) class I molecules which are recognized by the C8 T cells.  
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CD4 T cells are classified to different functional classes or T helper lineages based on their 
cytokine profile. The most studied lineages are the T helper 1 (TH1) and T helper 2 (TH2). TH1 
produce IFN-g, while TH2 produce IL-4, IL-5 and IL-1321. Recently a new class of helper T 
cells has been identified that express IL-17, TH17 cells22. The autoreactive CD4 T cells involved 
in MS have for a very long time been believed to be only of the TH1 type23. This is no longer 
the case, as lately the involvement of TH17 cells was also evident24. Furthermore, the number 
of TH17 cells in the CSF increases during relapse25. IL-17 producing cells were found to present 
in active and chronic MS lesions. These were CD4 T cells and interestingly also CD8 T cells, 
astrocytes and oligodendrocytes26. TH17 cells are able to start producing IFN-g under certain 
conditions27. Therefore, one must take into consideration the plasticity of the T helper cells, 
them being able to switch from one class to another depending on the surrounding cytokine 
environment28 , when characterizing the autoreactive T cells in MS.   
1.1.4.2 γ/δ T cells 
γ/δ T cells constitute approximately only 5% of the total T cell population in the blood 
circulation while in the skin and intestinal epithelium they are more common constituting 50% 
of the T cells. Moreover, unlike ab T cells, they recognize protein and non-protein antigens 
and do not require antigen presentation by MHC molecules (no MHC restriction)29. γ/δ T cells 
are part of both the innate and adaptive immune system, hence classified as innate-like T cells30. 
During their development in the thymus they can commit to a fate of IL-17 or IFNg secreting 
cells31. There is evidence of their involvement in MS pathology, earlier studies have identified 
expanded clones in acute MS plaques and CSF30 and even recent studies have examined the 
involvement of γ/δ T cells in the inflammatory process of MS32,33. 
1.1.4.3 B cells 
B cell involvement in MS autoimmunity has not been of great interest despite the presence of 
the Ig OCBs in the CSF and B cells forming lymphoid follicles in the meninges34. However, 
following the success of the anti-CD20 treatments, rituximab and ocrelizumab, more and more 
interest is directed towards B cell research in MS35,36. The role that B cells play in the immuno-
pathogenesis in MS is currently proposed to be antibody independent, mainly due to the fact 
that the antibody producing plasma cells do not express CD20 and OCBs are not much effected 
by anti-CD20 therapies37. The suggested antibody independent mechanisms are antigen 
presentation and cytokine production. Antigen presentation to T cells is an important step for 
their activation and differentiation. B cells express both pro- and anti-inflammatory cytokines 
and depending on their balance they can activate or downregulate the immune response38.  
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1.1.5 Treatments 
Unfortunately, there is currently no cure for MS. However, the introduction of the 
immunomodulatory treatments, resulting in changes in the immune system to a more regulatory 
or suppressive state, has been successful in reducing the number of relapses and providing a 
better quality of life for RRMS patients. 
1.1.5.1.1 Interferon beta 
Interferon beta (IFNb) is a polypeptide that is naturally present in the human body. It is a 
cytokine belonging to the type I interferons and is involved in the defense mechanism against 
viruses.  Recombinant forms of IFNb are the most widely used treatment for MS. They are 
IFNb-1a; administrated intramuscularly or subcutaneously and IFNb-1b; administrated 
subcutaneously. Treatment with IFNb reduces the annualized relapse rate (ARR) by 30% and 
MRI disease activity39. For SPMS patients IFNb treatment benefited only the reduction of 
relapse rate but not disability progression40, while showing no effect for PPMS patients41.  The 
mechanism behind its clinical effect is not quite understood, but it is believed that IFNb  shifts 
the cytokine milieu more to an anti-inflammatory state and reduces the crossing of the immune 
cells through the BBB42. 
1.1.5.1.2 Glatiramer acetate 
Glatiramer acetate is a synthetic peptide that has some similarity with the sequence of myelin 
basic protein (MBP). It is administrated subcutaneously and its suggested mode of action is 
that when it binds to the MHC class II molecules, either regulatory T cells (Tregs) are activated 
which cross react with MBP activated T cells and suppress them, or by binding to the MHC 
class II, glatiramer acetate competes with the binding of myelin antigens and hence reduces the 
activation of effector T cells43. Clinical trials for glatiramer acetate have shown a 29% reduction 
in ARR and also reduction of enhancing MRI lesions for RRMS44,45. 
1.1.5.1.3 Teriflunomide 
Teriflunomide is an orally administrated drug that exerts its immunomodulatory effect by 
inhibiting the mitochondrial enzyme dihydrooroate dehydrogenase which is essential for 
pyrimidine synthesis, thus inhibiting synthesis of pyrimidine and ultimately cell proliferation. 
How this benefits MS treatment is not totally understood, but it could be by reducing the 
proliferation of myelin autoreactive immune cells46. Its clinical efficacy is comparable with 
IFNb 47. 
1.1.5.1.4 Dimethyl fumarate 
Dimethyl fumarate (DMF) is an orally administrated immunomodulatory drug that 
demonstrates a marked reduction in ARR and MRI disease activity48. Its mechanism of action 
is still not fully understood, but it is thought to act mainly through the anti-oxidative nuclear 
factor (erythroid-derived 2)-like 2 (Nrf2) transcriptional pathway49. Mechanisms independent 
  6 
from the Nrf2 pathway have also been suggested50.  Recently, it was reported that patients with 
a favorable response to DMF treatment have an increased reactive oxygen species production 
by monocytes51. 
1.1.5.1.5 Natalizumab 
Natalizumab, is a humanized monoclonal antibody that binds to a4-integrin of the cell adhesion 
molecule VLA-4, blocking it from binding to its ligand VCAM1 on the surface of the 
endothelium. This prevents T cells in the peripheral circulation from crossing the BBB and 
gaining access to the CNS. Natalizumab is administrated intravenously and its clinical trials 
showed impressive results, reducing the ARR by 68%, the rate of disability progression by 
54% and gadolinium enhanced MRI lesions by 92% compared to placebos52. Treatment with 
natalizumab is coupled with the risk of developing of a rare devastating viral CNS infection, 
progressive multifocal leukoencephalopathy (PML). PML occurs as a consequence of 
reactivation of the John Cunningham virus (JCV), when the immune surveillance of the CNS 
is compromised by natalizumab. The incidence of PML in patients who have had the treatment 
for two years is 1 per 1000 patients53. As precautions for PML development, the titers of anti-
JCV antibodies are followed in patients treated with natalizumab for benefit–risk treatment 
decisions 54.   
1.1.5.1.6 Fingolimod 
Fingolimod is a structural analogue of sphingosine and it is the first oral drug approved for MS 
treatment. Sphingosine, when phosphorylated, binds to the sphinogsine-1 phosphate receptor 
type 1 (S1PR1) on the lymphocytes and induce their egress from secondary lymphoid organs.  
After phosphorylation, fingolimod binds to the S1PR1 which leads to internalization of the 
receptors, thereby preventing lymphocytes from exiting the secondary lymphoid organs55. 
Compared to placebo, fingolimod reduced the ARR by 48-55%, the rate of disability 
progression by 25-30% and gadolinium enhanced MRI lesions by 80% compared to 
placebo56,57. There are concerns for varicella zoster virus infection associated with fingolimod 
treatment58. Therefore, screening for previous infection and vaccination are recommended 
before treatment initiation. Fingolimod might cause transient bradycardia and atrioventricular 
block, thus when taking their first dose patients are monitored using electrocardiogram. 
1.1.5.1.7 Rituximab 
Rituximab is an anti-CD20 monoclonal mouse chimeric IgG1 that depletes CD20 B cells59. 
Currently it is approved for the treatment of B-cell lymphoma and rheumatoid arthritis, 
however the treatment of MS patients with rituximab is increasing in Sweden even though off 
label60. In Stockholm and Västerbotten counties, rituximab was found to perform better than 
natalizumab, fingolimod and DMF in regards to effectiveness and discontinuation (data not 
shown).  
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1.1.5.1.8 Other RRMS treatments 
Inducing lymphocyte depletion and immune reconstitution is also an effective treatment 
strategy and this can be achieved by the drugs cladribine and alemtuzumab61. In addition, 
autologous haematopoietic stem cell transplantation has been adopted for treating patients with 
a high disease activity62.  
1.1.5.1.9 Progressive MS treatment 
Options for treating the progressive course of MS is limited, however there are a number of 
ongoing and completed clinical trials of different strategies for preventing disability 
progression63. Two drugs which were promising for reducing disability progression are now 
approved for usage; ocrelizumab for PPMS64 and siponimod for SPMS65.  
 
1.2 MS ETIOLOGY 
MS is a complex disease in which both environmental and genetic factors are involved. The 
Rothman pie model66 has been used to explain this complexity. The model visualizes the 
environmental and genetic factors, which are the contributing factors, as slices of a pie which 
together make up sufficient cause for the disease to develop (“the whole pie”). Different 
sufficient causes can lead to development of the same disease and the same contributing cause 
could be shared in different sufficient causes (Figure 2).  
 
Figure 2.  The pies A and B are sufficient causes, while C is not sufficient because it misses 
the slice D (contributory cause). 
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1.2.1 Environmental risk factors 
Several environmental factors have been associated with the development of MS67. High 
vitamin D levels were found to be protective against MS and also reduce the hazard of relapses 
and MS brain lesions68,69. Cigarette smoking, as is the case with many other diseases, is a risk 
factor for MS70. In addition, MS patients who continue smoking after diagnosis have a worse 
prognosis than those who quit71. Working night shifts before the age of 20 was also identified 
as an MS risk factor72. Infectious mononucleosis, an infection caused by Epstein Barr virus 
(EBV) in adolescents and young adults, is also associated with the risk of developing MS73. 
1.2.2 Genetic risk factors 
Genetic inheritance of MS susceptibility is of important for the development of MS. This has 
been proven by familial risk and twin studies of MS patients and their relatives which reported 
high concordance rates for twins and increased risk for relatives of MS patients74,75. A meta-
analysis of the published familial recurrence risk data found that the age adjusted risk (AAR) 
was 18.4% for monozygotic (MZ) twins 4.61% for dizygotic (DZ) twins, 2.68% for siblings 
and 1.45% for  parents76. A recent study on the Swedish population has shown slightly lower 
AAR, with 17.26% for MZ twins, 1,92% for DZ twins and 2.55% for siblings77.  
In 1973, the first genetic locus associated with MS susceptibility was identified by a Danish 
group in the HLA class II region, then called the HLA7 78. With the development of genotyping 
techniques this association was further confirmed and the haplotype DRB1*1501-DQA1*0102-
DQB1*0602 was found to be associated with MS susceptibility79. Candidate gene association 
studies have identified a number of MS associated genes, including IL2Ra and IL7Ra80,81.  
1.2.2.1 MS Genome wide associations studies 
Based on the common disease common variant hypothesis, genome wide associations studies 
(GWAS), mainly in a case-control design, have been performed to identify susceptible 
common variants to MS. The advancement of microarray technology that allowed genotyping 
of SNPs covering the whole genome and the provision of thousands of patient samples through 
international collaborations (the international MS genetic consortium; IMSGC) have 
contributed to the success of GWAS in MS in the past decade82, discovering so far more than 
200 associated variants outside the MHC region with relatively small odds ratios reflecting a 
small effect size of these variants82.  Furthermore, these large numbers of associated variants 
explain only about 30% of the heritability of MS82. Hence the term “missing heritability” has 
been introduced also in to the field of MS genetics83, as well as in other complex autoimmune 
diseases84. There have been several suggestions of how to further the understanding of the 
genetics behind complex disorders and to facilitate the interpretation of the involvement of so 
many genetic variants with minor effects on disease development. These include the analysis 
of genetic pathways, study of rare genetic variants rather than common variants, more 
sophisticated analysis methods and whole genome or exome sequencing initiatives85.  
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1.2.2.2 Different types of genetic variants 
Variations in the human genome could range from a single nucleotide to a whole chromosome 
variation. Single nucleotide variants can be common or rare with the common variants have a 
frequency of 1% or more in the population. Common single nucleotide variants are known as 
single nucleotide polymorphisms (SNPs) occurring as mostly two different alleles of different 
frequencies. SNPs are widely studied as associated with the risk of developing a specific 
disease. Variations that are more than one nucleotide up to 1kb in the form of deletions or 
insertions are called indels. Furthermore, duplication or deletions of a DNA segment ranging 
from a couple of thousands to a few millions base pairs are described as copy number variations 
(CNVs). 
When the variation in the coding DNA sequence is different from the reference genome it is 
considered a mutation. Mutations can be hereditary or acquired. Hereditary mutations are 
inherited from the parents and is present in all cells, while acquired mutation is usually a 
consequence of an environmental effect or failure of DNA damage repair and is present in 
certain cells86. 
1.2.2.3 Somatic mosaicism 
Differences in the DNA sequence between individuals is always expected but not within the 
same individual between different tissues. The presence of such genetically distinct populations 
of somatic cells within an individual is called somatic mosaicism. This can be on the level of 
single nucleotides or whole chromosomes. An obvious example of somatic mosaicism is 
neoplasia, but there are also Mendelian disorders which may be characterized by somatic 
mosaicism, such as Fanconi anemia and Hemophilia A87. Although perhaps provoking, somatic 
variations in the form of CNV have also been reported in healthy individuals88,89. A form of 
somatic variation which is well recognized is the rearrangements in T cell receptor (TCR)s and 
B cell receptor (BCR)s that provides the diversity in T and B cells, respectively, which 
contributes to the diversity of the adaptive immune system. It was actually more than 60 years 
ago in 1957 that Burnet described this mechanism when he hypothesized that lymphocytes 
undergo ‘randomization’ of the genes coding the immunoglobulins in his clonal selection 
theory for the formation of antibodies90.  
There have been previous attempts to identify genetic variations specific to the brain in 
neurological diseases. CNV in the brain, but not in the peripheral blood, have been described 
in schizophrenia patients, but also in controls91. Another study by Pamphlett  et al92 identified 
CNVs which were unique to the brain of sporadic ALS patients when compared to their blood. 
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1.3 TCR 
TCRs are the transmembrane molecules through which the T cells recognize the antigens. They 
are a heterodimer of either an a and b or γ and δ chains that are produced during the maturation 
of T cells in the thymus through the rearrangement of multiple polymorphic genes to eventually 
produce either an ab or γδ TCR93. The a and γ chains are coded by variable (V), joining (J) 
and constant (C) genes and the whole region covering these genes are named the TCR a (TRA) 
and TCR γ (TRG) loci on chromosomes 14 (14q11) and 7 (7p14), respectively. The b and δ 
chains are coded by V, diversity (D), J and C genes. The TCR b (TRB) locus is situated on 
chromosome 7 (7q34) while the TCR δ (TRD) locus is situated within the TRA locus on 
chromosome 14 (14q11). Figure 3 illustrates reassembly of V(D)J genes in the process of TCR 
rearrangement. The diversity of the TCRs is mainly determined by the selection and 
rearrangement of the V(D)J genes, as the C genes are highly homologous. Furthermore, the 
region where the V(D)J genes are assembled together undergo additional nucleotide deletions 
or insertions producing a more unique sequence called the complementarity determining region 
(CDR)3. Hence, each T cell with a unique CDR3 sequence represents a distinctive T cell clone 
i.e. if two TCRs are coded by the same V(D)J genes they could still belong to two different 
clones. For every clone, each a or γ chain combine with a single b or δ chain, respectively. 
Therefore, determining the sequence of one of the chains is sufficient to identify the clone94.   
In project II of this thesis we have studied the T cell clonality through the analysis of the TRB 
repertoire by sequencing the TRB CDR3 sequence95.  
Figure 3. Illustration of the ab TCR rearrangement. A) Somatic reassembly of TRB and TRA 
loci. B) Coding TRB and TRA mRNA. C) ab heterodimer. [Figure reproduced from “De 
Simone, M., Rossetti, G. & Pagani, M. Single Cell T Cell Receptor Sequencing: Techniques 
and Future Challenges. Frontiers in Immunology 9, doi:10.3389/fimmu.2018.01638 
(2018)”]96 
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1.4 TCR DATABASE 
There are several databases for TCR sequences available for the public, e.g. Mc-PAS-TCR97 
and VDJdb98. TCR databases are a great resource of information, as they provide details of the 
reported CDR3 sequences and their target antigens if available and in which pathology or organ 
they were detected. In the context of MS, TCR databases are of great help to the scientific 
community, as the target antigen of the autoreactive T cells is still a mystery and the access to 
the target organ, the CNS, is invasive and excluding CSF samples, usually postmortem99.  TCR 
databases may hence limit the number of CNS samples required in individual studies and 
facilitate the identification of overlap between different studies. Furthermore, databases may 
improve understanding of the role of molecular mimicry in MS in case of the same CDR3 
sequence being reported to have different target antigens. 
 
1.5 BIOMARKERS 
 
The term biomarker is a commonly used term in the medical field, but what is a biomarker? 
One definition of a biomarker is “a characteristic that is objectively measured and evaluated as 
an indicator of normal biological processes, pathogenic processes, or pharmacologic responses 
to a therapeutic intervention.”100. Biomarkers are useful for disease screening, diagnosis, 
disease prognosis and activity monitoring, assessing treatment effect and response and 
treatment tailoring.  
One of the oldest biomarkers in MS is the OCBs which are oligoclonal IgG bands present in 
the CSF while absent in the plasma. The presence of OCBs is useful for the differential 
diagnosis of MS101 and even though OCBs are present in 95% of MS patients there has been 
hesitation in accepting it as a diagnostic tool9 until recently. After studies emphasized the 
significant role of OCBs in the diagnosis of MS102, it was recommended by the 2017 revisions 
of McDonald criteria, as a criterion to fulfill the dissemination in time in CIS patients with an 
established dissemination in space10. MRI is important for the diagnosis and monitoring of MS. 
MRI follow ups give information on new white matter lesions, the disease activity by 
measuring active inflammation and global CNS changes103. Neurofilament light chain (NfL), 
a component of the cytoskeleton of neurons, is a potential biomarker in MS. CSF levels of NfL  
is associated with the activity104 and progression of MS105. The serum and CSF levels of NfL 
are (luckily) correlated providing a more convenient access106. Treatment of MS patients with 
natalizumab reduced the levels of NfL in the CSF107, however it increased serum NfL before  
PML development, therefore NfL was suggested as a potential marker for early PML 
development108, while, finoglimod reduced the NfL levels in the CSF109 and plasma110. 
Therefore, NfL is a promising biomarker for MS progression and treatment response. Anti-
drug antibodies (ADAs) are a product of the immune system against biopharmaceuticals 
entering the body. A small portion of the patients treated with biopharmaceuticals will develop 
neutralizing ADAs (nADA) reducing the efficacy of the treatment111. Monitoring of ADAs in 
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connection with MS treatment is now common clinical practice in some countries. 
Furthermore, with the current line of management of individualized tailored medicine, the need 
for biomarkers in MS is rising. We need biomarkers which we can access without causing a 
great discomfort to the patient and being cost-effective at the same time.  
 
1.6 INTERLEUKIN-2, 6 AND 7 RECEPTORS 
The discovery of genetic associations is a foundation to identify the affected pathways and 
mechanisms in MS. Functional studies have shown that some of the associated variants can 
influence the expression of the genes. This is the case of rs6897932-C and rs1800693-G which 
promote alternative splicing of IL7R and TNFRSF1A transcripts, respectively, and the 
formation of the soluble form of their proteins112,113. In addition, in vivo studies have shown 
that the associated variants in IL7R and IL2R effect their soluble protein levels112,114.  
In two of the studies in this thesis, we have looked at the corresponding proteins of genes which 
have shown association with MS susceptibility and examined their biomarker potential.  
1.6.1 IL-2Ra 
Four decades ago, interleukin 2 (IL-2) was discovered115 as a crucial factor for T lymphocyte 
proliferation. Interleukin 2 receptor alpha (IL-2Ra; CD25) binds to IL-2 with a low affinity 
and does not transfer IL-2 signals without being in the trimeric complex of IL-2R with IL-2RB 
(CD122) and the common gamma chain (IL-2rg or gc)116. Presence of a soluble form of IL-
2Ra (sIL-2Ra ) in vitro was first described in 1985 by Rubin and colleagues117. Biochemically 
they described sIL-2Ra as a glycoprotein 10 Kd shorter than the membrane bound receptor 
and readily  binding IL-2118, hinting to an inhibitory effect of the soluble receptor. They also 
concluded that sIL-2Ra is mainly produced by proteolytic cleavage of the membrane bound 
receptor119. However, the production of the IL-2Ra without the transmembrane domain 
through an alternative splice variant of the IL2RA mRNA has been also demonstrated120. 
Therefore cells expressing the membrane receptor would be expected also to secrete the soluble 
receptor including T cells, B cells and monocytes121.  Many signaling pathways of IL-2 are 
linked to the beta subunit, including Janus kinases (JAK) and the signal transducer and activator 
of transcription (STAT)122 (Figure 4).  
After the identification of sIL-2Ra, many research labs studied its levels in different 
inflammatory contexts, including infections, post transplantation, malignancies and 
autoimmune diseases. Increased levels of serum sIL-2Ra were detected in patients with 
rheumatoid arthritis123, type 1 diabetes, Crohn’s disease, ulcerative colitis, systemic lupus 
erythematosus and  MS121. Hence, detecting increased levels of sIL-2Ra could be a surrogate 
for immune activation. In healthy individuals serum and urine soluble IL-2Ra  levels seem to 
be higher in children than in adults124,125, but whilst higher in the plasma of elderly than in 
young adults126 there seems to be no difference between females and males. 
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Both candidate and genome wide associations studies (GWAS) have implicated SNPs within 
the IL2RA  gene to be associated with MS susceptibility80, 127, 128. Using immunochip to study 
the immune related loci in a GWAS, the A allele of the SNP rs2104286 in the intron between 
exon 1 and 2 of the IL2RA gene was the non-HLA allele with the highest associated risk for 
MS128. Cerosaletti et al showed that having the MS risk haplotype for rs2014286 is correlated 
with reduced IL-2 signaling in CD4 T cells expressing high levels of IL-2Ra and that this IL-
2 reduced signaling is correlated with sIL-2Ra levels129. 
1.6.2 IL-6R 
Interleukin 6 (IL-6) is a multifunctional cytokine that has both inflammatory and anti-
inflammatory functions130 and is a major inducer of acute phase protein production by 
hepatocytes131. To exert its function, IL-6 binds first to the IL-6 receptor (IL-6R) on the cell 
membrane and then this complex binds to the signal transducing molecule glycoprotein 130 
(gp130) which then dimerizes and starts the signaling132 . This is known as the classic signaling 
of IL-6. IL-6 intra-cellular signaling passes through the JAK/STAT pathway, mainly STAT3 
and secondarily STAT1 as well as the mitogen activated protein kinase (MAPK) signaling 
pathway133. The classic signaling of IL-6 is limited to certain types of cells which express the 
IL-6R, including hepatocytes, megakaryocytes, monocytes, macrophages, B cells and subtypes 
of T cells134. The signaling transducing molecule gp130 is ubiquitously expressed and cells that 
do not express IL-6R receive IL-6 signaling through first forming a complex with a soluble 
form of IL-6R (sIL-6R) and then binding to gp130 on the surface of the cell135. Rose-John and 
Heinrich  named  this alternative signaling “IL-6 trans-signaling”136. sIL-6R is produced both 
by mRNA alternative splicing137 and protease cleavage by  metalloprotease ADAM17138 
(Figure 4). The classic signaling of IL-6 through the membrane bound IL-6R transfers the anti-
inflammatory effects of IL-6, while the IL-6 trans-signaling transmits the pro-inflammatory 
effects130. Kishimotos group managed to show also the existence of a soluble form of gp130 
(sgp130) and that this sgp130 inhibits IL-6 trans-signaling by binding to the IL-6/sIL-6R 
complex and preventing it from binding to the membrane bound gp130139 (Figure 4). sgp130 
is mainly produced by alternative splicing of the mRNA. IL-6 levels in the human peripheral 
circulation are about 1-5 pg/ml, which is 1000 times lower than the levels of sIL-6R at about 
50 ng/ml, while sgp130 levels are about 400 ng/ml140. IL-6 trans-signaling blocks the 
development of the autoimmune inhibitory Tregs cells from naïve CD4 T cells141 and favors 
the development of autoimmune inducing TH17-cells instead142, 143.   
In rheumatoid arthritis, the synovial fluid from arthritic patients showed increased levels of 
sIL-6R which corresponded to the advanced stages of the disease and leukocyte infiltration144, 
145 . The involvement of IL-6 in the pathogenesis of MS has also been of interest, from showing 
elevated expression in MS lesions, in CSF from MS patients and in peripheral blood 
mononuclear cells146,147, to failure of the development of MOG induced EAE in IL-6 deficient 
mice148. Conflicting results of higher and normal levels of IL-6 in the peripheral circulation of 
MS patients have been reported149,150. Regarding the studies of the receptors of IL-6 in MS, 
Padberg et al showed higher levels sIL-6R and sgp130 in the serum of MS patients compared 
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to healthy controls. IL-6 involvement in MS autoimmunity could be through both T cell and B 
cells. IL-6 is important for B cell differentiation and IgG production; hence its old name “B 
cell differentiation factor”151 and B cells from MS patients were shown to express high levels 
of IL-6 which could be lowered by the B cell depleting drug,  Rituximab152. Furthermore, IL-
6 secreted by B cells in the context of toll like receptors (TLR) activation increases the 
proliferation of effector T cells in vitro153. Effector T cells from RRMS patients have been 
shown to develop resistance to Tregs through the IL-6 signaling pathway154. Inhibition of IL-6 
signaling in the EAE model using IL-6r antibodies reduced the onset of the MOG induced EAE 
and the development of MOG specific TH17 and TH1 cells155. Based on these findings, 
tocilizumab, a humanized anti-IL-6R monoclonal antibody, has been suggested for MS 
treatment. 
1.6.3 IL-7Ra 
Interleukin 7 (IL-7) is an essential factor to T lymphocytes from their maturation and 
differentiation within the thymus156 to the survival and homeostasis of naïve and memory T 
cells in secondary lymphoid organs and peripheral circulation157. IL-7 production is not by the 
T lymphocytes themselves (as in the case of IL-2 and IL-6) but is produced mainly by stromal 
cells at primary and secondary lymphoid organs158. The signaling of IL-7 goes through binding 
to a heterodimeric receptor composed of Interleukin 7 receptor alpha (IL-7Ra; CD127) and the 
common gamma chain. This initiates mainly the JAK/STAT (STAT5) and phosphoinositide 3-
kinase (PI3K) signaling pathways159 (Figure 4). In 1990, a soluble form of the IL-7Ra (sIL-
7Ra)  that can bind to IL-7 was identified160. It is mainly produced by alternative splicing of 
the IL7RA transcript161, removing exon 6 which codes for the transmembrane domain. The 
concentration of sIL-7Ra in the peripheral circulation is about 1000 fold higher than its ligand, 
IL-7, ranging from 0,3-8,4 pg/ml162,163. The function of this soluble receptor still needs to be 
better understood. One study proposed an inhibitory effect to IL-7 activity164 and recently 
another study showed that sIL-7Ra increases the availability of IL-7 and enhances its activity 
112. 
Regarding the involvement of IL-7 in the process of autoimmunity, evidence point to its 
implication in type 1 diabetes and MS165. IL-7 signaling has also been shown to enhance the 
response of autoreactive T cells against myelin antigens from MS patients166. In addition, the 
expression of both IL-7 and IL-7Ra  proteins was found to be higher in the CSF of MS patients 
than in controls with other non-inflammatory neurological diseases81. Interestingly, actively 
suppressive Tregs are low expressers of IL-7Ra167. In addition, the major allele (C) for the 
SNP rs6897932, located in exon 6 of IL7RA, was the first allele outside the HLA region found 
to be associated with the risk for MS81. Later on, large cohort MS GWAS have confirmed the 
association of this SNP with MS risk127. Furthermore, presence of this MS associated allele is 
associated with increase in expression of the alternative transcript of the IL7RA, missing the 
transmembrane domain168. Likewise, an increase in the sIL-7Ra was associated with the 
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rs6897932 C allele in an allele dose dependent manner in MS patients, which was also 
accompanied by an increase in IL-7112. 
Figure 4.  Schematic view of IL-2 ,7 & 6 and their corresponding receptors, intracellular 
signaling molecules and effects. 
 
1.7 PEBP1 
This protein has multiple names, each one describing its different function, and is expressed in 
multiple tissues169. Phosphatidylethanolamine binding protein 1 (PEBP1) binds to the 
phospholipid phosphatidylethanolamine located at the cytoplasmic side of the plasma 
membrane. It is also known as hippocampal cholinergic neurostimulating peptide precursor 
protein (HCNP-pp), acting as a precursor of HCNP which has been shown to enhance 
acetylcholine synthesis in vitro170 . HCNP-pp is expressed both in the hippocampus and 
amygdala. Its expression was described to be lower in the hippocampus in Alzheimer patients 
compared to non-demented patients171, while elevated in the amygdala of females with major 
depression172. PEBP1 is also involved in the intracellular signaling, it inhibits the mitogen 
activated protein kinase (MAPK) pathway by binding and inhibiting RAF1 protein kinase, 
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hence the name RAF1 kinase inhibitor (RKIP)173. This inhibition of the MAPK pathways is 
essential for tumor suppression174. PEBP1 is also expressed in T cells and long term exposure 
to its derivative HCNP suppresses choline acetyltransferase expression and decreases the 
amount of acetylcholine175, conflicting its enhancement of acetylcholine synthesis in the 
hippocampus170. Hence, HCNP may act as a regulator in the lymphocytic cholinergic system 
that plays a role in the differentiation and proliferation of T cells176. 
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2 THESIS AIMS 
The general aim of this thesis is to explore genetic variants associated with MS and to further 
employ this knowledge to study potential MS biomarkers. 
I. To identify genetic variants associated independently to the progressive course of 
PPMS and to the relapsing course RRMS using exome sequencing data. 
 
II. To identify somatic mosaic sub-set of cells using CNVs that predispose specific 
immune cell to cross the BBB. 
 
III. To explore the potential role of the gene products of the MS associated variants 
IL7RA and IL2RA and IL6ST as biomarkers when monitoring MS treatment. 
 
IV. To utilize protein microarrays to identify potential biomarkers for MS treatment using 
serial plasma samples from MS patients.   
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3 METHODOLOGICAL CONSIDERATIONS 
3.1 PATIENTS AND CONTROLS SAMPLES 
All the samples collected from patients and controls were part of cohort studies approved by 
the Swedish ethical review authority. 
3.1.1 GEMS 
Genes and environment in multiple sclerosis (GEMS), is a population-based case-control 
study where prevalent cases are identified from the Swedish MS registry. The aim of GEMS 
is to study the interactions between genes and environmental factors in MS177. Controls are 
selected to match the patient’s age, sex and residential area. 
3.1.2 EIMS 
Epidemiological investigation of multiple sclerosis is a population-based incidence case-
control study to identify incident cases of MS70.  
3.1.3 STOPMS I & II 
Stockholm prospective assessment of MS (STOPMS) is an ongoing prospective study of the 
long-term development of MS in newly diagnosed MS patients and patients with neurological 
symptoms at the Karolinska University Hospital178. Controls are also recruited within the 
same hospital. 
3.1.4 IMSE I, II & V 
The Immunomodulation and MS Epidemiology (IMSE) I, II and V, are post marketing 
surveillance studies of Tysabri (natalizumab)179, Gilenya (fingolimod)180 and Tecfidera 
(Dimethyl fumarate) treatments in Sweden, respectively. The main aim of the IMSE studies is 
to evaluate the treatments safety and efficacy. In addition they facilitate studying the 
association between genetic variants and blood markers with disease activity, disability 
outcomes and side effects during treatment. 
3.2 CLINICAL DATA 
Patients’ clinical data were obtained from the Swedish MS registry181 and included information 
regarding their disease activity; relapses and brain and spinal cord magnetic resonance imaging 
(MRI) findings, and disease worsening and progression; expanded disability status scale 
(EDSS), multiple sclerosis severity score (MSSS), multiple sclerosis impact scale (MSIS29) 
and the symbol digit modalities test (SDMT). 
 
    19 
3.3 PAPER I 
3.3.1 SNPs and indels calling 
The GATK best practices workflow for germline short variants discovery v3.6 was applied for 
SNPs and indels calling182. The workflow comprises of three major steps, first a preprocessing 
step of aligning or mapping the raw sequencing reads to the reference genome, here we used 
the hg19 reference genome, followed by marking of the duplicate reads, then finally 
recalibration or correction of the quality or confidence scores for each base provided by the 
sequencing machine producing a BAM file per sample. From this BAM file the second step of 
variants calling, SNPs and indels calling, was proceeded using the HaplotypeCaller in GVCF 
mode to produce the intermediate file, GVCF file. Then multiple GVCF files from multiple 
samples were consolidated or combined creating a directory containing a GenomicDB 
datastore. Creating this directory is important for speeding up the following joint genotyping 
step using the joint genotyping tool, GenotypeGVCFs, outputting a combined genotyped multi-
sample VCF file. Then finally a filtering step, the Variant Quality Score Recalibration (VQSR) 
step, is done by assigning a quality score called the variant quality score log-odds (VQSLOD) 
to each variant calculated from a Gaussian mixture model based on highly validated datasets. 
Using the VQSLOD specified threshold variants are divided into quality tranches that can be 
used to filter the variants. Ultimately a final VCF file ready for downstream analysis is 
produced. 
3.3.2 CNVs calling from exome sequencing data 
In addition to calling SNPs and indels from the exome sequencing data we called CNVs using 
the CLAMMS tool183. The tool first divides exome capture regions into equally sized windows 
or regions and filter out regions with extreme GC content. Then the coverage values for each 
sample are normalized individually. CLAMMS, using the coverage from a reference panel of 
samples, performs a mixture model fitting each window to model its expected coverage 
distribution. Then finally CLAMMS applies a hidden Markov model using the normalized 
coverage values for the individual samples and the distributions from the fitted model to call 
the CNVs. 
3.3.3 Functional and clinical variants annotation 
Functional annotation of the called variants was performed using the ANNOVAR tool184. It 
gives information such as if the variant could change the amino acid sequence and if that might 
result in loss of function of the protein. For clinical relevant information on the variants, such 
as if the variant has been previously reported to be associated to a disease and with a deleterious 
effect or not, we have mined the ClinVardatabase185.  
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3.4 PAPER II 
3.4.1 Array CNV analysis 
For whole genome CNV analysis we used a DNA microarray which is designed specifically 
for CNV analysis, the CystoScan HD array (Affymetrix). This microarray includes 
approximately 2.7 million markers, where 750,000 are SNPs and 1.9 million are non-
polymorphic probes, with intragenic and intergenic marker spacing of 880 and 1,737 base pairs, 
respectively186. Normalization of the raw probe intensities to a reference panel and the paired 
peripheral blood (PB) and CSF CNV analysis were performed using the Nexus Copy Number 
software (BioDiscovery Inc, Hawthorne, CA). A threshold of a minimum five consecutive 
probes was used to call a CNV. 
3.4.2 Taqman copy number analysis 
To validate the CNVs identified from the genome wide screening we used Taqman copy 
number qPCR assays. For each identified CNV a set of probes, were selected to target its center 
and upstream and downstream genomic regions. To each reaction mix, a reference assay 
targeting the telomerase reverse transcriptase (TERT) gene was also included. The TERT gene 
is known to have two copies in a diploid genome, hence it can be used to normalize the target 
assay. CT values were imported to the CopyCaller™ Software (Applied Biosystems) to 
calculate the copy numbers of the target genes in the paired samples from each individual, once 
specifying PBMC sample as a calibrator. 
3.4.3 TCR sequencing 
We used high throughput TRB sequencing to investigate the TCR repertoire in paired CSF, 
CD4+ and CD8+ T cells. The LymphoTrack® TRB assay- MiSeq® kit (72250009, Invivoscribe) 
was used for library preparation, including multiplex primers that target the conserved Vβ and 
Jβ regions. Using the MiSeq Reagent Kit v2 (MS-102-2003, Illumina), paired-end 2x250 
sequencing was ran on the Illumina MiSeq platform. Each run composed of eight samples per 
flow cell, including three paired samples from two patients plus positive and negative controls. 
The raw FASTAQ data was then imported to MiXCR software187  to align the reads to the 
reference gene and then assemble the clonotypes identifying the CDR3 sequences of each 
clone. Downstream repertoire analysis was done using VDJtools188. 
3.5 PAPER III 
3.5.1 ELISAs for the quantification of sIL-7Rα, sIL-2Rα, sIL-6R and sgp130 
To measure the levels of sIL-7Rα in plasma we developed an in-house sandwich ELISA. In 
short, a monoclonal anti-human IL-7Rα (R&D systems) was used to coat a 96 well plate and 
after an overnight room temperature incubation period the plate was washed and blocked. The 
next day, after washing and blocking the plate, 1:20 diluted plasma samples and 7-point 
standard curve, prepared using recombinant human IL-7Rα Fc chimera (R&D systems), were 
added to the plate. The bound IL-7Rα was detected using a biotinylated polyclonal anti-human 
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IL-7Rα (R&D systems). After adding streptavidin-HRP and its substrate a color developed. 
The developed color is in proportion to the amount of IL-7Rα and its intensity was measured 
on a spectrophotometer using 450nm filter. To measure sIL-2Rα, sIL-6R and sgp130, 
commercially available ELISA kits (R&D systems) were used. All samples from the same 
patient were included in the same ELISA plate to avoid inter-plate variations. 
3.5.2 Genotyping data 
MS associated variants were genotyped using the MS replication chip, a customized Illumina 
array developed for the IMSGC189. 
3.6 PAPER IV 
3.6.1 High throughput proteins measurements 
In paper IV, we utilized the high throughput multiplex affinity array, antibody suspension bead 
array, to measure the levels of 59 proteins in serial plasma samples targeted with 90 antibodies. 
These antibodies had been generated as part of the HPA project190 and we adopted a previous 
protocol by Drobin et al with slight modifications 191. Briefly, antibodies were coupled to color-
coded magnetic beads and then combined in a suspension buffer creating the bead array. 
Plasma samples were labelled with biotin after dilution 1:10 in phosphate buffer saline. After 
labelling the samples were diluted 1:16 in an assay buffer and heat treated for 30 minutes at 
56ºC and then added to the bead mixture distributed into 384-well plates. Then the plate was 
washed and streptavidin conjugated fluorophore added. Lastly, the plate was measured in a 
FlexMap3D instrument (Luminex corp.) and median fluorescence intensity (MFI) was reported 
for each bead identity. 
3.6.2 ELISAs for antibodies specificity validation  
The specificity of the PEBP1 antibody, HPA008819 (Atlas antibodies), was validated using an 
indirect and a sandwich ELISA. The RTN3 antibody, HPA015649 (Atlas antibodies), 
specificity was validated using an indirect and an inhibition ELISA. For more details regarding 
the ELISAs please refer to the materials and methods section of paper IV. 
  22 
 
Figure 5. Illustraion of the protocol of the antibody suspension bead array. A) Plasma samples 
are distributed into a microtiter 384-well plate. B) Biotin labelling of the proteins in the sample. 
C) Antibodies are coupled to color-coded magnetic beads and then mixed together to form the 
suspension bead array. D) Samples are heat treated and then combined with the beads mixture. 
E). The array is measured in a Luminex FlexMap3D instrument using two lasers to measure 
the intensity values (red laser) and to identify the bead with the coupled antibody (green laser). 
[Figure reproduced from “Darmanis, S. et al. Identification of candidate serum proteins for 
classifying well-differentiated small intestinal neuroendocrine tumors. PLoS One 8, e81712, 
doi:10.1371/journal.pone.0081712 (2013).”]192 
 
3.7 STATISTICAL METHODS 
3.7.1 Association tests for exome sequencing data 
Association tests for the common variants obtained from the exome sequencing data were 
performed using the logistic Wald test on EPACTS version 3.3.0193. To correct for sex and 
relatedness, 20 principal components were obtained from the kinship matrix generated by the 
vcf2kinship tool that is part of the Rvtest package194and added to the logistic regression model. 
A p-value threshold of 5.5x10-7 and 5.5 x10-5 was selected for an exome-wide significant and 
suggestive associations, respectively. 
Association tests for rare variants are usually performed on a group of variants within a gene 
instead of single variants separately so as to increase the statistical power, known as gene-based 
association tests195. There are several methods for gene-based rare variant association tests and 
in paper I we have applied two methods. One is a burden test called the combined multivariate 
and collapsing (CMC) method196, which assumes that all variants within the gene have the 
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same effect and their information is collapsed into a single score that is used for the association 
test. The second test we used is a combination of two methods, the burden test and the variance-
component test (SKAT test) that takes into account that variants in the gene could have 
different effects on the trait (increase or decrease the risk), called the SKAT-O197. Genes with 
a p-value <0.1x10-5 were considered to be significantly associated. 
3.7.2 Frequency distribution testing 
In paper II to test for the difference in the frequency distribution of expanded T cell clones 
between patients during relapse or remission we used the Pearson’s Chi-squared test.  
3.7.3 Linear mixed effect model 
To test for the changes in the protein levels in a longitudinal manner during a period of 
approximately 24 months of treatment we used the linear mixed effect model. The benefit of 
using this model is that it deals with the random effect of having multiple measurement from 
the same individual while taking into consideration the fixed effects in the individual e.g. age 
and gender. We used this model in papers III and IV using the R package “LmerTest”198. 
3.7.4 Correcting for multiple testing  
In paper IV, we utilized a multiplex protein array profiling 59 proteins, which necessitates the 
correction for multiple testing. Therefore, Bonferroni correction was applied to adjust the p 
values using the “multitest” package199. 
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4 RESULTS AND DISCUSSION 
4.1 PAPER I 
We have utilized whole exome sequencing data from RRMS, PPMS and population-based 
control (PBC) to identify genetic variants that are associated to each course of MS 
independently, i.e. RRMS and PPMS. The association tests were conducted on three levels, 
PPMS vs PBC, RRMS vs PBC and PPMS vs RRMS. 
The association of HLA class II genes (HLA-DRB1, HLA-DQA1 and HLA-DQB1) was 
replicated in both PPMS and RRMS. All significant associations in the HLA region 
disappeared after correction for HLA-DRB1*15 and A*02. Noticeably, the known protective 
association of the class I allele HLA-A*02 for RRMS19 was not detected for PPMS. Outside 
the HLA region, when comparing PPMS to PBC, the locus of the pseudogene (RP11-693J15.3) 
on chromosome 12 carried one significantly and three suggestively associated indels to PPMS 
risk. Two nonsynonymous SNPs in the VCAN gene on chromosome 5 were also suggestively 
associated to PPMS. VCAN codes for the protein versican that belongs to the family of 
proteoglycans are one of the major constituents of brain extracellular matrix. In the edges of 
active brain white matter plaques of MS patients, versican  was found to be increased 200.  
When comparing RRMS to PBC outside the HLA region, we identified novel suggestive 
associations in the CCL25, JMJD1C, LYZL2 and TIMM44 genes to RRMS. A replication of 
these novel associations is desirable. CCL25 is a chemokine that is involved in T cell 
maturation and their recruitment to the intestine201. The expression of CCL25 was observed to 
be increased in the synovial fluids of rheumatoid arthritis patients and its antagonists are studied 
for the treatment of irritable bowel disease202. Within the suggestive association category, we 
also replicated several previously associated risk genes; PHACTR2203, P2RX7204 and 
PRKRA205. Genetic variants in PHACTR2 and PRKRA were also reported by others to be 
associated to the risk of Parkinson’s disease and ankylosing spondylitis, respectively206,207. 
Lately, the associated variants in PRKRA were retracted by the authors because they noticed 
that the alleged associated variants are rather a duplication of a true associations in the HLA 
region and in strong LD with them208. Nevertheless, we detected a frameshift mutation and this 
association survived the HLA alleles correction. The previously reported P2RX7 association to 
MS was on the protective side204 and this protective association was also observed in our study. 
PPMS to RRMS comparisons have shown a number of significant associations even though 
the number of samples was limited. To RRMS, we identified an intergenic SNP on 
chromosome 4 that was significantly associated and an indel in TRBV7-3 on chromosome 7 
that was suggestively associated. TRBV7-3 was reported to encode for the variable b chain of 
a T cell receptor specific for MBP209,210. To PPMS, we identified one significantly associated 
SNP in FAM53C and another six SNPs and one indel were suggestively associated. Four of the 
six SNPs are in the Lysine demethylases gene family (KDM1B and KDM3B). FAM53C 
encodes a protein that belongs to a family of nuclear proteins that are known to be involved in 
the neural tube development211. KDM1B and KDM3B proteins act as specific histone 
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demethylases leading to chromatin remodeling and similar histone modifications and 
chromatin remodeling have been highlighted in neuronal differentiation, survival and 
neurodegenerative diseases212.  
For identifying rare variants associations, we took a gene-based approach which resulted in 
observing multiple suggestive associations. The top two associations were INO80D to RRMS 
when compared to PBC and GBP5 to PPMS when compared to RRMS. GBP5 stimulates the 
inflammasome NRLP3 which is known to be tangled in the neuro-inflammatory process of 
many neurodegenerative diseases213,214. 
CNV analysis revealed 12 significant associations, including a deletion in LCE3C locus that 
had a lower frequency in PPMS (79%) compared to both RRMS (87%) and PBC (88%). 
Deletions in this locus is common in the general population and have also been associated to 
psoriasis and rheumatoid arthritis215-217.  
We mined for clinically significant mutations and a total of 187 and 31 clinically relevant 
pathogenic variants were identified in PPMS and RRMS, respectively. Focusing on mutations 
that were reported in MS and other neurological diseases, 15 were present in PPMS and 6 in 
RRMS. In PPMS, four mutations were hereditary spastic paraplegia (HSP) related mutations. 
This enrichment for HSP mutations in PPMS has also been reported recently by Jia et al218. 
Interestingly, another two were previous MS associated mutations, CYP27B1p.Arg389His and 
NR1H3p.Arg415Gln which is a subject of dilemma in regards of its association to MS219-221. 
These findings shed light on the genetic distinctiveness of PPMS from RRMS and on the fact 
that PPMS patients carry causative genetic variants of progressive neurological disorders that 
might help in understanding the progressive course of MS. 
4.2 PAPER II 
Based on the hypothesis that somatic mosaic genetic variants predispose specific immune cell 
to cross the BBB and become involved in the inflammatory process in the CNS we compared 
CNVs between CSF cells and PBMCs.  
Using an Affymetrix array which is tailored for CNV detection we screened the whole genome 
for CNVs in paired CSF cells and PBMCs from six RRMS patients, one PPMS patient and two 
healthy controls. The comparison of these cells from either side of the BBB revealed deletions 
in the TCR loci; TRA/D, TRG and TRB in CSF cells. These deletions were confirmed using 
Taqman assays. When we sorted CD4+, CD8+ and γδ T cells from the PBMCs and compared 
them to the CSF cells a more complex pattern of these CNVs was detected. Deletions in TRG 
and TRA/D were consistent between all cell types except the TRA/D deletions in γδ T cells. 
Deletions in the TRB locus were mainly absent in γδ T cells and showed inter-individual and 
intra-variations between CSF, and CD4+ and CD8+ T cells. These findings suggested that these 
deletions are likely a result of the classic form of somatic mosaicism, TCR rearrangement. In 
a Japanese cohort, deletions in the TRG and TRA/D loci were associated with the risk of MS 
using DNA from PBMCs222. These deletions were validated only in T cells when different 
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white blood cells subsets were sorted to correct for the DNA source and concentration. Despite 
the deletions only being present in the sorted T cells, the authors speculated that their finding 
cannot be explained by TCR rearrangement as the complete J genes from the TRG loci were 
deleted. In another context, childhood allergic asthma, lower copies of the TRG loci was also 
associated to the risk of the disease223. This CNV in childhood allergic asthma was stated by 
the authors to be a mosaic somatic mutation as they were not inherited form their parents. 
The absent TRA/D deletions in the γδ T cells suggests that the CSF cells are mainly αβ and not 
γδ T cells. Other studies have implicated γδ T cells in MS33, expanded γδ T cells were shown 
to be present in acute MS plaques and CSF30 and a subtype of γδ T cells was reported produce 
IFN- γ in a correlation with disease activity224. A fair comparison between isolated γδ T cells 
from the CSF and the periphery would be preferable, but this is challenging because of the 
small number of CSF cells. Even if we would manage to isolate γδ T cells from the CSF, 
another hurdle is to be able to extract enough yield of DNA. However, we did detect deletions 
in the TRB locus that are not expected according to the sequential TCR rearrangement225. 
Although this could be a result of sample contamination with αβ T cells, we dismiss that 
explanation as we then also expect to have detected deletions in the TRA locus, which we did 
not. Yet concurrent rearrangement of β, γ and δ loci226 could explain these deletions.  
The multifaceted deletions in the TRB locus have encouraged us to study and profile the T cell 
repertoire both in the periphery and central nervous system by sequencing the rearrangements 
in the TRB locus. Applying a frequency threshold of 0.1% for clonal expansion, the CD4+ T 
cells were the most diverse compared to CD8+ T cells and CSF cells, while CD8+ T cells was 
the least diverse. In the periphery, it was also reported before that CD8+ T cells are more 
expanded or less diverse than CD4+ T cells227. A small number of CSF T cell clones were 
shared with the peripheral CD4+and CD8+ T cells, 7.2% and 4.9% of CSF T cell clones 
overlapped with CD4+and CD8+ T cells, respectively. This indicates a divergence in the TCR 
repertoire and compartmentalized expansion of the clones228. 
Dividing our TCR repertoire profiled cohort based on their clinical status of relapse (n=3) or 
remission (n=2) showed a less diverse or more expanded repertoire during relapse in all three 
compartments (CSF; p=0.0001, CD4+ T cell; p=0.005 and CD8+ T cell; p=0.037). This 
observation should be replicated in a larger cohort. Repertoire expansion or restriction might 
have a role in acute exacerbation of the disease. Agreeing with our results, a study with 
longitudinal CSF samples taken at relapse and remission, showed a reduced diversity of TRB 
repertoire at relapse229. In addition, natalizumab treatment reduced the repertoire expansion in 
the periphery but increased it in the CSF230. The after treatment increase in repertoire restriction 
may seem contradictory with our results, but as explained by the authors, this could be due to 
that the remaining cells in the CSF are selected T cells with autoantigen specificity230.  
It would be very interesting to know the target antigens of the identified clones. Therefore, we 
mined the antigen specific TCR sequences database, VDJdb98, and identified the target antigens 
of several of the identified TCR sequences. The majority were viral antigens including the EBV 
antigens, which are of great interest because of EBV infection is a well-documented 
    27 
environmental risk factor for MS231. In our identified repertoire, 3/4 of the expanded clones 
with known antigen specificity were targeting EBNA3A and EBNA3B antigens, but not 
EBNA1, which is the EBV antigens believed to be the main target for the humoral response232.  
In summary, with the ambition to identify novel variants that can be associated to MS and 
explain its missing heritability we screened for somatic CNVs and identified deletions in the 
TCR loci that were further revealed to be a consequence of specific TCR rearrangements which 
could potentially provide the basis for sub-populations of cells within the CNS. Our approach 
can assist in identifying autoreactive T cells and their corresponding antigens in MS and other 
autoimmune diseases. 
4.3 PAPER III 
After the successful GWASs in MS127,128, a good number of genes have been highlighted for 
their possible role in the inflammatory process in MS. Here we studied how two of the effective 
immunomodulatory drugs, natalizumab and fingolimod, effect the peripheral protein 
expression levels of some of the genes with known involvement in the immune 
response112,154,233,234. The studied patients were first on natalizumab and then switched to 
fingolimod, as a precaution from developing PML after being positive for JC-virus 
antibodies235. 
We analysed changes in the levels of the soluble cytokine receptors; sIL-7Rα, sIL-2Rα, sIL-
6R and sgp130, in serial plasma samples from before and after starting the treatment with 
natalizumab and then followed by fingolimod. Samples were collected approximately in the 
first 24-month treatment period for each drug and using the linear mixed effect model, we 
assessed the changes of the plasma levels of these soluble cytokine receptors from baseline and 
at 6, 12 and 24 months of treatment. This was done in two separate cohorts (cohort 1; n=47 and 
cohort 2; n=57) and similar results were obtained when analyzing each cohort separately or 
combined, therefore the results presented here is for the combined analysis. During 
natalizumab treatment the levels of sIL-7Rα and sgp130 decreased significantly while sIL-2Rα 
and sIL-6R levels did not change. The following fingolimod treatment lead to a significant 
increase of sIL-7Rα and sgp130, sIL-2Rα decreased significantly while sIL-6R remained 
unchanged.  
Both natalizumab and fingolimod effect the peripheral lymphocyte count but in the opposite 
direction. Natalizumab increases the number of lymphocytes236, hence we would expect an 
increase in the levels of these soluble receptors. Unpredictably, the only change we observed 
was a slight significant decrease in sgp130 and sIL-7Rα levels during treatment. Fingolimod 
decreases radically the number of lymphocytes in the periphery (70 % reduction) as a result of 
trapping them in the secondary lymphoid organs57 and therefore a decrease in the levels of the 
soluble cytokine receptors is expected. Indeed, the levels of sIL-2Rα decreased significantly 
but it was disproportionate to the level of reduction in lymphocyte count. On the contrary, 
sgp130 and sIL-7Rα levels increased during fingolimod treatment and sIL-6R did not change. 
We checked for the correlation between the lymphocyte count and soluble cytokine receptors 
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levels and the only significant correlation was a negative correlation with sgp130, which could 
help in explaining the increase in the sgp130 during fingolimod treatment. 
To assure that the changes in the levels of the soluble cytokine receptors is not a result of a cell 
count effect, we studied a group of patients treated with dimethyl fumarate (DMF). DMF 
causes lymphopenia through inducing apoptosis237. Our DMF treated cohort was divided into 
a group that developed lymphopenia and another with normal cell count. The results showed 
that both groups had no changes in the levels of the soluble cytokine receptors. The 
lymphopenia observed during fingolimod treatment is reversible as the cells are still present 
but just redistributed238, hence one would expect a more sound effect of lymphopenia in DMF 
treatment if such an effect was the cause of the change of receptors levels during fingolimod 
treatment. Therefore, we hypothesized that the decrease of sIL-2Rα and increase of sgp130 and 
sIL-7Rα is a direct effect of fingolimod treatment. One reported effect is as an intranuclear 
histone deacetylase (HDAC) inhibitor, that enhances histone acetylation and acetylation and 
subsequently gene expression239.  To test if the changes in the levels of these cytokine receptors 
is a direct effect of fingolimod and not a consequence of the sequestration of the cells, we 
cultured PBMCs for up to nine days in three different conditions; with fingolimod, 
phosphorylated fingolimod or just the vehicle. At day nine, the most significant results were 
that the levels of sIL-2Rα were significantly lower when the cells were treated with fingolimod 
than phosphorylated fingolimod or vehicle (Figure 6). These cell culture results may explain 
the decrease in the levels of sIL-2Rα that we observe in the plasma of fingolimod treated 
patients, but not the increase in sgp130 or sIL-7Rα. 
 
Figure 6. PBMCs cultured for up to nine days in three conditions; with fingolimod or 
phosphorylated fingolimod or just the vehicle. The levels of a) sIL-2Rα b) sIL-6R c) sgp130 
and d) sIL-7Rα were measured from the supernatant and the differences in the concentrations 
between the three conditions were tested for using the linear mixed model. * P value< 0.05, ** 
P value< 0.01, *** P value< 0.001. 
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The increase in sgp130 during fingolimod treatment might result in a desired anti-inflammatory 
response. Sgp130 is known to block the pro-inflammatory IL-6 trans-signaling pathway139 that 
otherwise favors the development of autoimmune inducing TH17-cells142,143 to inhibitory Tregs 
cells from naïve CD4 T cells141. TH17-cells are involved in the neuro-inflammatory process24,25 
and reducing their number would be a favorable outcome. Fingolimod does reduce TH17-cells 
count, however this effect has been attributed to their sequestration240. This might be plausible, 
nevertheless we suggest that blocking of their trans-signaling pathway through increasing 
sgp130 might contribute to reducing TH17-cells. 
We managed to replicate the association of the risk allele of the SNP rs6897932 with higher 
levels of sIL-7rα in plasma112. In addition, we observed a pharmacogenomic effect of the risk 
allele of rs6897932 during fingolimod treatment, in that sIL-7rα levels increase significantly 
more in patients homozygous for the risk allele than in other groups.  
In this study, we were able to report the effect of the MS treatments on soluble cytokine 
receptors. These observed effects, even though they may appear as collateral or a consequence 
of the main effects, can still be valuable in other contexts, as they may have similar effects as 
anti-IL-6 or anti-IL2 drugs241,242. This encourages further studying of these treatments 
pharmacodynamics. 
4.4 PAPER IV 
With the general ultimate goal to tailor MS treatment for each patient, we took advantage of 
the advancement in the proteomics technology and utilized protein microarrays to identify 
potential biomarkers for MS treatment. We used the antibody suspension bead array, that had 
been useful in detecting biomarkers in neurological243,244 and non-neurological disorders245,246, 
and had proven to perform multiplex protein profiling in plasma samples243,246.  
Antibodies were selected for targeting and profiling proteins that are involved in the pathways 
of MS associated genetic risk variants128, markers of inflammation, expressed in the CNS and 
had been interesting in previous MS protein profiling studies244,247.  First, we profiled a total of 
59 proteins in serial plasma samples of patients who have been on natalizumab and then 
switched to fingolimod (as a screening cohort we used the 44 patients of the paper III cohort 
1). Here also we applied the linear mixed effect model to test for the changes in the measured 
protein levels during the first 24 months of each treatment period separately and a coefficient 
cut off of 0.25 and a p value < 0.001 were used. For a total of 10 antibodies, significant changes 
of the target protein levels were detected during the period of natalizumab treatment with no 
significant changes during fingolimod treatment (Figure 7). 
  30 
Figure 7. Scatter plot of the coefficients and adjusted p values obtained from the linear mixed 
effect model. Changes in the detected protein levels during natalizumab treatment (circles) and 
fingolimod (triangles) were considered significant (dark red) after using a cut off value of 0.25 
for the coefficient and a p value < 0.001. 
To confirm the reliability of the antibody array results we validated the specificity of the 
antibodies HPA008819 and HPA015649 targeting PEBP1 and RTN3, respectively. We 
developed two different types of in-house ELISA for each protein. For HPA008819, an in-
house indirect ELISA and a sandwich ELISA and for RTN3 we developed an indirect ELISA 
and an inhibition ELISA. In the same screening cohort, we managed to reproduce the decrease 
in PEBP1 levels during natalizumab treatment and we also observed a decrease in the RTN3 
levels, but they were not significant. Furthermore, in an independent cohort of MS patients 
treated with natalizumab, we replicated only the decrease in PEBP1 levels. One explanation 
for failing to reproduce the RTN3 observation from the protein array could be that, for the 
array, the plasma samples are heat-treated which affects the conformation of the protein and 
facilitate epitope accessibility248. However, we tested for this and observed no difference 
between heat-treated and non-treated plasma samples. Another possible explanation could be 
that the measurements obtained by the inhibition ELISA were not accurate. 
Following the change in the disability outcomes, EDSS and MSSS, for all the patients included 
in this study reflects that the treatment response to natalizumab was quite good. To tell if the 
decrease in PEBP1 levels is a consequence of the positive treatment response or a treatment 
effect we combined both the screening and replication cohorts and studied the changes in 
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PEBP1 and RTN3 levels in two groups of patients, with the highest (moderate responders) or 
the lowest (mild responders) decrease values for the disability outcome, MSSS, during 
natalizumab treatment. Both PEBP1 and RTN3 decreased significantly in the moderate 
responder group while the levels did not change in the mild responders, which favors the 
treatment response rationalization. In support, the decline in PEBP1 was also observed in 
patients treated with DMF.   
PEBP1 is expressed in the hippocampus and in patients with the neurodegenerative disease, 
Alzheimer's disease (AD), this protein is less present than in non-demented patients171. In 
addition, its derivative protein, HCNP, was reported to be high in the CSF of AD patients249. If 
we consider that the observed peripheral measurements of PEBP1 mirrors the neuro-
inflammation and neurodegeneration, the decrease of PEBP1 during treatment might reflect 
the reduction in neurodegeneration.  
In summary, we applied a semi hypothesis free approach to identify biomarkers for MS 
treatment using high-throughput proteomics technology. This approach succeeded in detecting 
the intra-individual change in the levels of several promising proteins, one of which is PEBP1, 
where we could reproduce and replicate its decline during treatment. This encourages further 
studies of the role of PEBP1 in MS and its potential as a biomarker for MS treatment. 
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5 CONCLUSIONS AND FUTURE PERSPECTIVES 
Our knowledge of MS immuno-pathogenesis is increasing by the day especially with the 
current available immunomodulatory treatments (Figure 8). The scientific community had not 
really reached a consensus that MS is an autoimmune disease until these treatments have 
proven their efficiency.  
There is a clear distinction between RRMS and PPMS clinically and pathologically to some 
extent, however genetically no variants have been identified to distinguish RRMS from 
PPMS250. This was reasoned by that the sufficient number of PPMS patients were not present, 
in other words, insufficient sample size. Nevertheless, a number of alleles have been suggested 
to be possibly associated with PPMS risk, such as APOE ε4 allele, CASP8 GG homozygous 
SNP of rs2037815 and IL-4R Q551*R251. In addition, most of the identified MS associated 
gene variants fall outside the coding regions82. In paper I, we targeted the coding regions using 
whole exome sequencing in a modest number of PPMS and compared them to RRMS and 
PBC. One of the main findings is that in PPMS we didn’t observe the strong protective 
association of class I allele HLA-A*02 for RRMS.  In addition, we identified an indel in the 
TCR gene TRBV7-3 suggestively associated to RRMS when compared to PPMS, this might 
emphasize the importance of antigen recognition and T cell activation in the course of RRMS 
but not in PPMS. Even though our PPMS cohort is of limited size, to our knowledge it is the 
largest cohort that an exome sequencing has been performed on. It would be interesting to see 
how increasing the size of the cohort will affect the suggestive associations, will they become 
stronger or disappear. 
Most of the MS genetic studies are based on acquiring DNA from peripheral blood while the 
main target organs are found separated from the periphery by the BBB. This approach has 
nevertheless been successful in identifying germinal genetic variants under the common 
disease common variant hypothesis. On the other hand, there is an increasing interest in 
studying the role of somatic genetic variants in MS252,253. In paper II we studied the contribution 
of somatic variants to MS in a periphery - CNS comparison of peripheral and CSF cells, where 
peripheral cells were the reference samples. This approach, we believed, may detect genetic 
variants that will predispose immune cells to cross the BBB and take part in the inflammatory 
milieu in the CNS. We identified deletions in the TCR loci that are consistent with 
rearrangements of the TCR genes. This further emphasize the significance of the specificity of 
the immune reaction. The initial genome wide CNVs screening was performed in a small 
number of patients and healthy controls and in unsorted PBMCs and CSF cells. Adding more 
individuals and sorting the cells from the periphery and the CSF might help in revealing 
somatic variants in other regions. Nevertheless, it would be interesting if we could follow the 
TCR repertoire profile after treatment and isolate the expanded T cells and determine their 
targets using protein arrays. 
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The information of the associated MS risk genetic variants is available for the scientific 
community to build on and to understand how they contribute to the pathophysiology of MS. 
Functional studies have been successful in identifying the consequences of some of the 
associated variants112,234.  In papers III and IV, we took advantage of these findings and studied 
the gene products of the MS associated loci and their potential use as biomarkers for monitoring 
natalizumab and fingolimod treatments. This was in conjunction of using longitudinally 
collected plasma samples which was possible because of the huge efforts in the longitudinal 
treatment surveillance cohorts. These cohorts provide the possibility of detecting intra-
individual changes. In paper III, we observed changes during treatment in plasma levels of the 
soluble cytokine receptors sIL-7Rα, sIL-2Rα and sgp130 but not sIL-6r. Studying these 
changes in correlation to the disability measurements was quite challenging as most of the 
patients were good responders to the treatment. Whether these cytokine receptors could be used 
as biomarkers is a valid question that needs further studying, especially in a well characterized 
patient cohort on the basis of disease activity. The unchanged sIL-6R levels during treatment 
is puzzling even though both natalizumab and fingolimod have strong immunomodulatory 
effects and one would expect some changes to occur when either the immune cells are blocked 
from entering the CNS or captured in the lymph nodes. In addition to the gene products of the 
MS associated loci in paper IV we profiled the expression of CNS proteins and inflammatory 
markers in plasma where nine proteins exhibited decreasing levels during treatment. We choose 
to validate the top two proteins with the most significant changes, PEBP1 and RTN3. Yet, it 
would be interesting to validate the changes of the other seven proteins including e.g. GFAP, 
which previously has been reported as potential biomarker for disease progression104, although 
its CSF levels did not change after natalizumb treatment107. 
If the identified genetic variants from the PPMS versus RRMS exome sequencing analysis are 
replicated they may support the question if PPMS is an independent entity from RRMS. In 
addition, they could also be candidates for disease progression genetic studies and assist the 
ongoing efforts in these studies. The approach that we took in paper II in identifying 
subpopulations of immune cells that cross into the CNS is in line with the efforts of finding 
therapies that target specific cell clones and not all cell lineage or subsets. This might help in 
reducing the possibility of infections and malignancies during treatment as the patient will not 
be immune compromised. The era of personalized medicine is here, medical practitioners are 
more aware now of the individual differences and they are adjusting to them, especially with 
the availability of multiple treatment options. In papers III and IV, we studied the effect of 
treatment on the protein expression in plasma with a main focus on the individual variation and 
observed variations in some of the proteins during treatment. Even though these variations did 
not correlate with the clinical variables, these observations might help in further understanding 
how the treatment works and to identify other possible effects on the immune system than the 
originally intended, which might assist in finding new indications for the treatments or the 
development of new treatments. 
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Figure 8. Proposed MS pathogenesis.                                             Created with biorender.com 
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